Paradoxical bleeding and thrombotic episodes of dysprothrombinaemia due to a homozygous Arg382His mutation

Summary

We have characterised the pathogenic basis of dysprothrombinaemia in a patient exhibiting paradoxical bleeding and thrombotic defects during pregnancy and postpartum. Genetic analysis revealed that the proband is homozygous for the prothrombin Arg382His mutation, possessing only ~1 % clotting activity. The proband experienced severe bleeding episodes during her pregnancy, which required treatment with prothrombin complex concentrates, and then pulmonary embolism and deep-vein thrombosis at 28 days postpartum, which required treatment with LMWH and fresh frozen plasma. Analysis of haemostatic parameters revealed that the subject had elevated FDP and DD and decreased fibrinogen levels, indicating the presence of hyperfibrinolysis. Thrombin generation and clotting assays with the proband’s plasma in the presence of soluble thrombomodulin and tissue-type plasminogen activator indicated a defect in activation of both protein C and thrombin activatable fibrinolysis inhibitor (TAFI). Unlike normal plasma, no TAFI activation could be detected in the patient’s plasma. The expression and characterisation of recombinant prothrombin Arg382His indicated that zymogen activation by prothrombinase was markedly impaired and the activation of protein C and TAFI by thrombin-Arg382His was impaired 600-fold and 2500-fold, respectively. The recombinant thrombin mutant exhibited impaired catalytic activity toward both fibrinogen and PAR1 as determined by clotting and signalling assays. However, the mutant activated factor XI normally in both the absence and presence of polyphosphates. Arg382 is a key residue on (pro)exosite-1 of prothrombin and kinetic analysis of substrate activation suggested that the poor zymogenic activity of the mutant is due to its inability to bind factor Va in the prothrombinase complex.

Supplementary Material to this article is available online at www.thrombosis-online.com.

Keywords

Prothrombin - protein C - fibrinogen - TAFI - fibrinolysis

• References

• 1 MacGillivray RT, Degen SJ, Chandra T. et al. Cloning and analysis of a cDNA coding for bovine prothrombin. Proc Natl Acad Sci USA 1980; 77: 5153-5157.
• 2 Furie B, Furie BC.. The molecular basis of blood coagulation. Cell 1988; 53: 505-518.
• 3 Esmon CT, Owen WG, Jackson CM.. The conversion of prothrombin to thrombin V. The activation of prothrombin by factor Xa in the presence of phospholipid. J Biol Chem 1974; 249: 7798-7807.
• 4 Mann KG, Butenas S, Brummel K.. The dynamics of thrombin formation. Arterioscler Thromb Vasc Biol 2003; 23: 17-25.
• 5 Pedersen LC, Yee VC, Bishop PD. et al. Transglutaminase factor XIII uses proteinase-like catalytic triad to crosslink macromolecules. Protein Sci 1994; 03: 1131-1135.
• 6 Bajzar L, Morser J, Nesheim M.. TAFI, or plasma procarboxypeptidase B, couples the coagulation and fibrinolytic cascades through the thrombin-thrombomodulin complex. J Biol Chem 1996; 271: 16603-16608.
• 7 Mosnier LO, Meijers JC, Bouma BN.. Regulation of fibrinolysis in plasma by TAFI and protein C is dependent on the concentration of thrombomodulin. Thromb Haemost 2001; 85: 5-11.
• 8 Esmon CT.. Molecular events that control the protein C anticoagulant pathway. Thromb Haemost 1993; 70: 29-35.
• 9 Dahlbäck B, Villoutreix BO.. Molecular recognition in the protein C anticoagulant pathway. J Thromb Haemost 2003; 01: 1525-1534.
• 10 Walker FJ, Fay PJ.. Regulation of blood coagulation by the protein C system. FASEB J 1992; 06: 2561-2567.
• 11 Coughlin SR.. Protease-activated receptors in haemostasis, thrombosis and vascular biology. J Thromb Haemost 2005; 03: 1800-1814.
• 12 Estevez B, Kim K, Delaney MK. et al. Signalling-mediated cooperativity between glycoprotein Ib-IX and protease-activated receptors in thrombin-induced platelet activation. Blood 2016; 127: 626-636.
• 13 Mosnier LO, Griffin JH.. The cytoprotective protein C pathway. Blood 2007; 109: 3161-3172.
• 14 Benezra M, Vlodavsky I, Ishai-Michaeli R. et al. Thrombin-induced release of active basic fibroblast growth factor-heparan sulfate complexes from subendothelial extracellular matrix. Blood 1993; 81: 3324-3331.
• 15 Peyvandi F, Mannucci PM.. Rare coagulation disorders. Thromb Haemost 1999; 82: 1207-1214.
• 16 Sun WY, Coleman MJ, Witte DP. et al. Rescue of prothrombin-deficiency by transgene expression in mice. Thromb Haemost 2002; 88: 984-991.
• 17 Sun WY, Witte DP, Degen JL. et al. Prothrombin deficiency results in embryonic and neonatal lethality in mice. Proc Natl Acad Sci USA 1998; 95: 7597-7602.
• 18 Akhavan S, De Cristofaro R, Peyvandi F. et al. Molecular and functional characterisation of a natural homozygous Arg67His mutation in the prothrombin gene of a patient with a severe procoagulant defect contrasting with a mild hemorrhagic phenotype. Blood 2002; 100: 1347-1353.
• 19 Acharya SS, Coughlin A, Dimichele DM. North American Rare Bleeding Disorder Study Group. Rare Bleeding Disorder Registry: deficiencies of factors II, V, VII, X, XIII, fibrinogen and dysfibrinogenemias. J Thromb Haemost 2004; 02: 248-256.
• 20 Peyvandi F, Duga S, Akhavan S. et al. Rare coagulation deficiencies. Haemophilia 2002; 08: 308-321.
• 21 Strijks E, Poort SR, Renier WO. et al. Hereditary prothrombin deficiency presenting as intracranial haematoma in infancy. Neuropediatrics 1999; 30: 320-324.
• 22 Girolami A, Scarano L, Saggiorato G. et al. Congenital deficiencies and abnormalities of prothrombin. Blood Coagul Fibrinolysis 1998; 09: 557-569.
• 23 Morishita E, Saito M, Kumabashiri I. et al. Prothrombin Himi: a compound heterozygote for two dysfunctional prothrombin molecules (Met-337-->Thr and Arg-388-->His). Blood 1992; 80: 2275-2280.
• 24 Henriksen RA, Owen WG, Nesheim ME. et al. Identification of a congenital dysthrombin, thrombin Quick. J Clin Invest 1980; 66: 934-940.
• 25 O’Marcaigh AS, Nichols WL, Hassinger NL. et al. Genetic analysis and functional characterisation of prothrombins Corpus Christi (Arg382-Cys), Dhahran (Arg271-His), and hypoprothrombinaemia. Blood 1996; 88: 2611-2618.
• 26 Sekine O, Sugo T, Ebisawa K. et al. Substitution of Gly-548 to Ala in the substrate binding pocket of prothrombin Perijá leads to the loss of thrombin proteolytic activity. Thromb Haemost 2002; 87: 282-287.
• 27 Miyawaki Y, Suzuki A, Fujita J. et al. (2012) Thrombosis from a prothrombin mutation conveying antithrombin resistance. N Engl J Med 2012; 366: 2390-2396.
• 28 Djordjevic V, Kovac M, Miljic P. et al. A novel prothrombin mutation in two families with prominent thrombophilia--the first cases of antithrombin resistance in a Caucasian population. J Thromb Haemost 2013; 11: 1936-1939.
• 29 Sivasundar S, Oommen AT, Prakash O. et al. Molecular defect of ’Prothrombin Amrita’: substitution of arginine by glutamine (Arg553 to Gln) near the Na(+) binding loop of prothrombin. Blood Cells Mol Dis 2013; 50: 182-183.
• 30 Bulato C, Radu CM, Campello E. et al. New Prothrombin Mutation (Arg596Trp, Prothrombin Padua 2) Associated With Venous Thromboembolism. Arterioscler Thromb Vasc Biol 2016; 36: 1022-1029.
• 31 Bode W, Mayr I, Baumann U. et al. The refined 1. 9 A crystal structure of human alpha-thrombin: interaction with D-Phe-Pro-Arg chloromethylketone and significance of the Tyr-Pro-Pro-Trp insertion segment EMBO J 1989; 08: 3467-3475.
• 32 Lane DA, Philippou H, Huntington JA.. Directing thrombin. Blood 2005; 106: 2605-2612.
• 33 Rezaie AR.. Reactivities of the S2 and S3 subsite residues of thrombin with the native and heparin-induced conformers of antithrombin. Protein Sci 1998; 07: 349-357.
• 34 Yang L, Manithody C, Rezaie AR.. Activation of protein C by the thrombin-thrombomodulin complex: cooperative roles of Arg-35 of thrombin and Arg-67 of protein C. Proc Natl Acad Sci USA 2006; 103: 879-884.
• 35 Chen L, Yang L, Rezaie AR.. Proexosite-1 on prothrombin is a factor Va-dependent recognition site for the prothrombinase complex. J Biol Chem 2003; 278: 27564-27569.
• 36 Mosnier LO, von dem Borne PA, Meijers JC. et al. Plasma TAFI levels influence the clot lysis time in healthy individuals in the presence of an intact intrinsic pathway of coagulation. Thromb Haemost 1998; 80: 829-835.
• 37 Geng Y, Verhamme IM, Smith SA. et al. Factor XI anion-binding sites are required for productive interactions with polyphosphate. J Thromb Haemost 2013; 11: 2020-2028.
• 38 Ding Q, Yang L, Dinarvand P. et al. Protein C Thr315Ala variant results in gain of function but manifests as type II deficiency in diagnostic assays. Blood 2015; 125: 2428-2434.
• 39 Wang W, Nagashima M, Schneider M. et al. Elements of the primary structure of thrombomodulin required for efficient thrombin-activable fibrinolysis inhibitor activation. J Biol Chem 2000; 275: 22942-22947.
• 40 Anderson PJ, Nesset A, Dharmawardana KR. et al. Role of proexosite I in factor Va-dependent substrate interactions of prothrombin activation. J Biol Chem 2000; 275: 16435-16442.
• 41 Rezaie AR, Cooper ST, Church FC. et al. Protein C inhibitor is a potent inhibitor of the thrombin-thrombomodulin complex. J Biol Chem 1995; 270: 25336-25339.
• 42 Yang L, Manithody C, Qureshi SH, Rezaie AR.. Factor Va alters the conformation of the Na+-binding loop of factor Xa in the prothrombinase complex. Biochemistry 2008; 47: 5976-5985.
• 43 Müller F, Mutch NJ, Schenk WA. et al. Platelet polyphosphates are proinflammatory and procoagulant mediators in vivo. Cell 2009; 139: 1143-1156.
• 44 Choi SH, Smith SA, Morrissey JH.. Polyphosphate is a cofactor for the activation of factor XI by thrombin. Blood 2011; 118: 6963-6970.
• 45 Von dem Borne PA, Bajzar L. et al. Thrombin-mediated activation of factor XI results in a thrombin-activatable fibrinolysis inhibitor-dependent inhibition of fibrinolysis. J Clin Invest 1997; 99: 2323-2327.
• 46 Tollefsen DM.. Vascular dermatan sulfate and heparin cofactor II. Prog Mol Biol Transl Sci 2010; 93: 351-372.
• 47 Bae JS, Kim YU, Park MK. et al. Concentration dependent dual effect of thrombin in endothelial cells via PAR-1 and PI3 Kinase. J Cell Physiol 2009; 219: 744-751.